Cardiovascular disease (CVD) remains a leading cause of mortality globally. Traditional risk assessment models often rely on static factors, limiting their predictive accuracy. This review explores the potential of artificial intelligence (AI) and machine learning in enhancing CVD risk prediction. We delve into the integration of blood pressure measurements, particularly ambulatory blood pressure monitoring (ABPM) and office blood pressure (OBP), into AI-powered models. By analyzing the current state of research, we highlight the opportunities and challenges in developing AI-driven risk calculators for early CVD detection and prevention.
Cardiovascular disease (CVD) is a complex and multifaceted health condition with devastating consequences. Early identification and risk stratification are crucial for effective prevention and management. Traditional risk assessment models, while valuable, often rely on a limited set of static factors, potentially overlooking individuals at high risk. Recent advancements in artificial intelligence (AI) and machine learning have opened new avenues for improving CVD risk prediction.
Blood pressure is a fundamental biomarker for assessing cardiovascular health. Ambulatory blood pressure monitoring (ABPM) provides a more comprehensive picture of blood pressure patterns throughout the day and night compared to traditional office blood pressure (OBP) measurements. Both ABPM and OBP are valuable data points for predicting CVD risk.
AI and machine learning algorithms offer the potential to analyze vast amounts of data, including clinical, demographic, and lifestyle factors, to identify complex patterns associated with CVD risk. By incorporating blood pressure data, AI models can enhance predictive accuracy and identify individuals at higher risk of developing CVD.
While AI holds immense promise, several challenges must be addressed:
Data Quality and Availability: High-quality, comprehensive datasets are essential for training robust AI models.
Model Interpretability: Understanding the underlying factors influencing AI-generated predictions is crucial for clinical adoption.
Ethical Considerations: Ensuring fairness and avoiding bias in AI models is paramount.
Despite these challenges, the potential benefits of AI-driven CVD risk prediction are substantial:
Early Detection: Identifying individuals at high risk early in the disease process allows for timely interventions.
Personalized Medicine: Tailoring prevention and treatment strategies based on individual risk profiles.
Improved Patient Outcomes: Early detection and intervention can significantly reduce morbidity and mortality.
AI and machine learning have the potential to revolutionize CVD risk prediction. By integrating blood pressure data, particularly ABPM, into sophisticated models, we can move closer to a future where CVD is effectively prevented and managed. Addressing the challenges and conducting rigorous research are essential to unlock the full potential of AI in this critical area of healthcare.
1.
Aspirin Fails to Boost Survival in Colorectal Cancer Trial
2.
Do Anatomy Atlases Reflect Social Inequalities?
3.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
4.
Some triple negative breast cancers might be avoided by longer breastfeeding
5.
Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Metabolic Competition Within the Tumor Ecosystem: Mechanisms, Clinical Relevance, and Therapeutic Advances
3.
Ferroptosis-Modulating Nanocarriers for Solid Tumor Therapy
4.
Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients
5.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Excellence in Hematology
2.
Navigating the Complexities of Ph Negative ALL - Part I
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Understanding the causes of anemia in adults beyond nutritional deficiencies
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation